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During its 25th anniversary year, the
National Alopecia Areata Foundation
undertook a project to completely re-
evaluate their research program and to
help focus and direct future directions of
alopecia areata (AA) research to better
meet the goals of people with AA and
the scientists working to discover the
mechanisms of disease and better treat-
ments for AA. This project was embo-
died in three research summits in 2008,
2009, and 2010. The first summit was
an evaluation of the progress of AA
research in a global sense, with an
emphasis on how to use the research
programs to bring better treatments to
patients. The second summit focused on
immunology and how to better under-
stand the autoimmune nature of AA. A
major objective was to identify drugs
used in other autoimmune diseases to
treat AA. The third summit focused on
developing a clinical research network
that could most effectively bring new
treatments to patients. These three sum-
mits laid the foundation for the fourth
summit in the series: From Base Pairs to
Bedside: Innovations in the Immunology
and Clinical Science of Alopecia Areata.
In 2007, the National Alopecia Areata
Foundation (NAAF) celebrated its 25th
anniversary with a great sense of accom-
plishment and anticipation, finding itself
at a challenging and exciting threshold
of a new era of research in alopecia
areata (AA). Its pilot funding for young
investigators had developed a genera-
tion of young scientists, who are now
competitive for NIH funding. Its stew-
ardship was instrumental in the funding
of the National Alopecia Areata Registry
(NAAR). Initially funded since 2000 by
Award Number HHSN268200682279C
from the National Institute of Arthritis
and Musculoskeletal and Skin Diseases
(NIAMS), one of the institutions in the
National Institutes of Health (NIH), the
government provided over six million
dollars to establish the NAAR and gather
initial information and samples. Federal
funding for the registry ended on 31
March 2012, at which time NAAF inher-
ited it. In helping the registry to get
underway, NIAMS indicated its strong
commitment to research regarding AA
for which we will always be grateful.
The Scientific Advisory Council of NAAF
convinced the Board of Directors to host
a research summit in Bethesda, MD,
USA to evaluate the state of research in
AA and to help chart the future direc-
tions of research and potential sources of
funds to support that future.
NAAF 2008 Research Summit
The first NAAF research summit con-
vened in Bethesda, Maryland on 11 July
2008. Forty-four participants were
selected to include experts in the fields
of genetics, immunology, patient regis-
tries, autoimmunity, animal models,
drug development, plus NAAF staff and
donors, and NIAMS program staff.
A wide-ranging program covered many
topics: genetics, effective use of registry
data, autoimmunity and immunology,
hair follicle stem cells and signaling,
neuroscience, animal models, drug
development and paths to drug disco-
very. It was clear that genetic research
in AA had emerged as the poster child
of a successful NAAF initiative depen-
dent on the NAAR. Other areas of
research clearly needed further support
and an organized approach to develop-
ment.
The first priority identified in forward-
ing research in AA leading to a cure was
to support the continued development
and maintenance of the NAAR. The
patient database and repository of serum
and DNA in the Registry had already
led to a major genome-wide association
study (GWAS) project (Petukhova et al.,
2010) and multiple diverse research
projects. After 10 years of NAAF pilot
funding, Dr Christiano and colleagues
have secured substantial NIH funding
to support AA genetics research, based
on a seminal GWAS study using
NAAR patient material. As the 10-year
funding of the NAAR by NIAMS was due
to end in 2011, the first priority was to
develop a succession plan for conti-
nuation of the NAAR to maximize the
development of epidemiological, genetic,
immunological, and clinical studies.
The second priority was to encourage
immunological studies to better under-
stand the mechanisms of disease in AA,
to characterize the specific antigenic
targets of autoimmunity in AA, to explore
ways to reverse the loss of immune
privilege (IP) in AA, and to take advan-
tage of the many drugs being developed
to treat other autoimmune disease. The
recommendations to achieve this goal
were to:
1. Convene a summit of leading immu-
nologists to develop directions of
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immunological research in AA and
create new RFAs (Request for Appli-
cations) based on the summit recom-
mendations;
2. Explore the immune status of the hair
follicle in long-standing disease,
including melanocytes and other cell
populations;
3. Employ immunopharmacologists to
identify drugs already in Phase 1
studies that might be useful for test-
ing in AA; and
4. Actively pursue the approved Food
and Drug Administration (FDA) use
of topical immunotherapy, which
has been used effectively but hapha-
zardly for the past 30 years.
The third priority was to develop a
plan to use the C3H/HeJ animal model
to screen FDA-approved drugs for use in
AA. It was believed that this approach
would shorten development time and
cost for new treatment approaches.
NAAF had established a contract with
Jax-West to validate the C3H/HeJ model
using standard effective treatments in AA
and then to move on to a list of possible
treatments used in other autoimmune
diseases or discovered in AA research.
This summit was a turning point in
AA research. By analyzing the current
state of research in AA, NAAF and the
AA research community were able to
define clear goals, prioritize research
objectives, and make a firm commit-
ment in identifying new treatments for
AA. A robust plan for fund raising and
eventual plans for RFAs was proposed to
focus future research directions.
NAAF 2009 Immunology Research
Summit
This research summit was held in
Denver, CO, USA on 21 August 2009.
The purpose was to evaluate the state
of immunology research in AA and to
identify those areas of immunology
research that should be supported by
NAAF. To accomplish this, NAAF con-
vened major AA researchers working
in genetics, immunology, neurobiology,
and clinical research. NAAF also invited
a diverse group of immunologists work-
ing in T-cell biology, allergy, tole-
rance, autoimmunity, and translational
research in autoimmunity.
Background
Maria Hordinsky, MD, University of
Minnesota, introduced the meeting
attendees to AA, a common auto-
immune disease highly associated with
atopy controlled by genetics and the
nervous system. Amos Gilhar, MD,
Technion-Israel Institute of Technology
and Flieman Medical Center, reviewed
the classic xenograft animal model
experiments that showed that AA is a
CD4- and CD8-mediated disease in
which hair follicle melanocytes are the
target, especially the antigens gp100,
MART-1 (melanoma antigen recog-
nized by T cells 1), and tyrosinase.
Jean Claude Bystryn, MD, New York
University, showed that autoantibodies
are common in human AA and in the
C3H/HeJ model and that the antibody
specificities are quite different from the
antibody specificities in human vitiligo.
Ralf Paus reviewed the data that sup-
ports the hypothesis that a major factor
in AA pathogenesis is the breakdown of
IP in the hair follicle. He proposed a
complex mechanism of IP and new
drugs that might reverse the breakdown
of IP in AA. John Sundberg, DVM, PhD,
The Jackson Laboratory, proposed that
the C3H/HEJ mouse is the best model
for adoptively transferrable rever-
sible immune hair loss, which can be
transferred by CD8þ cells. Angela
Christiano, PhD, Columbia University,
presented a comprehensive and careful
study of genetic associations in AA,
which implicated T cells and natural
killer (NK) cells and NK cell–activating
ligands. These new findings show upre-
gulation of NK-activating peptides in the
connective tissue sheath around AA hair
follicles. Donald Leung, MD, PhD,
National Jewish Medical and Research
Center, explored the possible connec-
tions between atopy and AA and raised
some important questions about future
research directions, especially the study
of steroid resistance in AA treatment.
What we do not yet know:
1. The role of NK, NKT, regulatory
T cells, and T helper type 17 (Th17)
cell populations in AA patients with
early, middle, and late stages of
disease;
2. Identity of the antigens recognized
by autoantibodies;
3. Whether NK cells are involved in
induction or maintenance of disease;
4. Whether the pathway to disease in
the C3H/HEJ mouse is the same as in
patients with AA;
5. The genetic definition of disease
subsets in AA;
6. The role of barrier dysfunction in AA
and whether there is a relationship to
atopy; and Does atopy influence or
determine disease severity or course?
Is it a factor in induction or expan-
sion of disease?
Discovery and New Technologies
Yehuda Shoenfeld, MD, PhD, Tel-Aviv
University Israel, discussed funda-
mental, unmet needs in autoimmunity
research, most of which are highly
relevant to AA: the effects of vitamin
D, infectious triggers of autoimmunity,
the hygiene hypothesis, and molecular
mimicry. Phillipa Marrack, MD,
National Jewish Health, confirmed her
belief that ‘the T cell is the center of the
universe’, but conceded that in AA we
should ‘look at autoantibodies and work
backwards’ to understand the antigen
that triggers AA. Knowing the antigen
helps us understand the mechanism of
disease, how tolerance is broken, and
may lead to therapeutic targets. Jeffrey
Frelinger, PhD, University of Arizona,
presented the proposition that we
should knock out antigen-specific T
cells to treat AA. Yosef Refaeli, PhD,
University of Colorado Denver, dis-
cussed the issues of IP, immune ignor-
ance, and immune tolerance. George
Eisenbarth, MD, PhD, University of
Colorado Denver, discussed modern
approaches to the study of auto-
immunity in diabetes, including studies
of antibody specificity, use of biologics,
induction of oral tolerance as treatment,
development of anti-TCR antibodies,
and use of NCI small molecule libraries
to block the binding of antigen/TCR
or antibody in autoimmune disease.
Stephen Miller, PhD, Northwestern
University, presented the potential of
treating autoimmune disease by re-esta-
blishing tolerance to self-antigens that
are the target of disease. He is applying
this approach in organ transplant-
ation and in the treatment of multiple
sclerosis; the concept is to induce the
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destruction of autoreactive T cells early
in disease.
Outcome of Summit and Future
Research Directions
The summit provided a number of
recommendations for future research to
advance the research into the immune
mechanisms of AA:
1. Solidify research collaborations initi-
ated at the Alopecia Areata Immuno-
logy Research Summit; and
a. Analysis of sera for autoantibodies
and antibodies against viruses.
Outcome: Registry sera sent to
Yehuda Shoenfeld for study of
autoantibodies and virus-specific
antibodies.
b. Discover antigen specificity
through study of autoantibody
specificity in AA. Many attendees
at the summit supported this as
the first best step in characterizing
the specificity of the immune
response in AA.
Outcome: Li Zhang Ph.D. com-
pleted a research project with
Dr Eisenbarth in 2012 to measure
autoantibodies from AA patients
against 32 antigens found in the
human hair follicle using stan-
dard radioimmuno assay. Daisy
Dai will identify autoantibodies
against human hair follicle anti-
gens by screening a library of
DNA clones expressing genes for
all hair follicle antigens with anti-
bodies from AA patients, and then
sequence and identify the clones
to determine antibody specificity.
c. Development of new animal
models for AA
Outcome: Development of a
humanized mouse model for AA
with a human immune system and
engrafted hair-bearing skin from
an AA patient to study immune
mechanisms of hair follicle dam-
age and/or destruction. (Refaeli,
Gilhar co-PI). Animal model
project funded by private philan-
thropy 2011.
2. New research initiatives to be funded
through NAAF RFP
a. Restoration of IP to reverse AA
Outcome: IP project funded by
NAAF 2011 (Paus PI)
b. There was great interest in target-
ing NK cells and Th17 cells in
AA in recognition of the emerging
importance of these cell popula-
tions in autoimmunity. Infectious
triggers in AA were proposed as
possible therapeutic targets.
Attacking specific effector popu-
lations of acquired immunity in
AA is the holy grail of specific
immune therapy.
Outcome: Support future projects
to clarify autoimmune specificity
and mechanisms in AA.
3. Establish a clinical research consor-
tium based on NAAR sites (plus
others) driven through partnerships
with NIH and Industry. NAAF will
lead the effort to develop a team to
screen the literature for potential
new targets and prioritize them.
New opportunities will be explored
through RFAs, using funds from
new partners for philanthropy and
research support. They will also mar-
ket the NAAR for use in these studies.
2010 Clinical Research Summit on the
Immunology of Alopecia Areata
The Clinical Research Summit on the
Immunology of Alopecia Areata met at
Columbia University in New York City
on 22 October 2010. The purpose of
this summit was to discuss the need for
new treatments in AA patients, to dis-
cuss new scientific and translational
opportunities that point to new thera-
pies, and to discuss new strategies to
bring these treatments to patients.
A major priority at this summit was to
explore alternative avenues to new
therapies, using drugs already used in
other autoimmune diseases. The atten-
dees at the summit provided a prelimi-
nary list of drugs: targretin with steroid,
hedgehog drug (sonic hedgehog analog)
to ‘‘jumpstart’’ anagen, Anakira (inter-
leukin (IL)-1 pathway inhibitor), stat
(signal transducer and activator of tran-
scription factor) 4 inhibitor, FK506 with
vehicle from Transderm, anti-interferon-g
(anti-IFN-g) antibody, and drugs that
target NGF (nerve growth factor) or
Substance P peptide or receptor inhibi-
tor, aMSH (alpha-melanocyte-stimulat-
ing hormone) or MC1R (melanocortin-1
receptor) inhibitors (pigmented hair
follicles are targets in AA).
New Treatments are Demanded by AA
Patients
As clearly stated by Maria Hordinsky,
‘Patient groups are demanding more!!!’
The Mission of the Alopecia Areata
Clinical Research Group is to ‘fast track’
possible treatments that are both effec-
tive and safe. Members of the team are
already investigating new promising
approaches: Excimer laser (McMichael),
Targretin (Duvic), Zithranol (Shapiro),
and new autoimmune therapies (multiple
investigators). Recruiting new research
partners to help develop new treatments
will be greatly facilitated by better qual-
ity-of-life (QOL) data, which is now
being collated from the NAAR database.
Previous Failed Treatments
Over the past 5 years, significant effort
has been invested in studying promising
therapies, including modern biologics,
as treatments for AA. So far Efalizumab
(Raptiva), Alefacept (Amevive), and Eta-
nercept (Enbrel) have all been ineffec-
tive. Why were these trials ineffective?
Some suspected that the study of alope-
cia universalis or AT patients may have
been too difficult a challenge; patchy
persistent disease (50–75% hair loss on
the scalp) might be more appropriate for
initial trials. Maria Hordinsky felt that
previous biopsies establishing the
inflammatory phase of AA are necessary
before instituting immunosuppressive
drugs. Angela Christiano suggested that
studies might need a hedgehog agonist
to stimulate anagen follicle activation.
Wilma Bergfeld, MD, FAAD, Cleveland
Clinic, added that minoxidil might need
to be added as an accelerator. David
Whiting, MD, Texas Hairskin Research
and Treatment Center, felt that patients
needed to be staged as acute, subacute,
and chronic before enrollment in stu-
dies. It is evident that there is still
disagreement on the best clinical stage
of disease to enroll in modern treatment
protocols.
What are Appropriate Drugable Targets
in the AA Immune Response?
Raphael Clynes, MD, PhD, Columbia
University, provided a detailed discus-
sion of the best drug targets in
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autoimmunity: innate/NKG2D response
(UBLP3, UBLP6, MICA), antigen-pre-
senting cells (APC)/sentinel (human leu-
kocyte antigen, TAP2, IFN-g), and
adaptive immunity (CTLA4 (cytotoxic
T-lymphocyte-associated antigen-4),
iCOS (inducible costimulator), IL-2,
IL2R, IL-21). IL-15 drives the NKG2D
axis and may itself be a good target.
Most of the genes upregulated in AA are
IFN-g response genes, so blocking IFN-g
effects is a logical approach. CTLA4
inhibition may enhance regulatory
T-cell suppressor cells, inhibit Th1 cyto-
kines, and inhibit CTL—which would
block the immune response in AA. Jak
inhibitors might block Th1 cytokines
that drive AA. Syk is expressed by CTL
in AA, and inhibitors might limit dis-
ease. These treatments fall into three
broad categories: blocking NK innate
immunity, putting the brakes on acti-
vated T cells, and jamming the inflam-
matory cytokine network. Many of these
targets were uncovered in the GWAS
study led by Angela Christiano.
New Treatment Opportunities Based on
Drugs Being Developed for Other
Autoimmune Diseases
Elise Olsen, MD, Duke University Medi-
cal Center, reviewed the possible drug
candidates available for topical and
systemic use and discussed some of
the pitfalls facing drug development in
AA. To repurpose FDA-approved drugs,
we would need to perform fairly large
clinical trials because of the large spon-
taneous remission rate in AA. For drugs
that are not yet FDA approved, selection
of drugs in Phase III of development
would be most practical. She also noted
that we need better consideration of
topical agents, such as topical nitrogen
mustard, cyclosporine, or imiquimod. It
is clear that a number of drugs are great
candidates for testing in AA; all of these
are drugs in development or are already
FDA approved.
Drug Action
Anti CD25 Kills activated T cells
Anti-CTLA-4 Blocks CD86-dependent
activation of APC
Jak ½ Inhibitor blocks Th1 response
(Continued)
Drug Action
Anti-NKG2D Inhibits NK cells
Syk inhibitor Blocks T cells
Anti-IL-15 Upstream of NK and T-cell
activation
Anti-IL-6 Upstream of TY cell activation
Anti-IFN-c Downstream from T-cell
activation and NK
Anti-TAP2 Blocks antigen processing
Anti IL-1 Blocks cytokine cascade
Anti-IL-17 Inhibit effects of Th17 cells
Anti-PDE4 Blocks T-cell activation
Review of Different Drug Delivery
Systems
Timothy Weidmann, PhD, University of
Minnesota, reviewed the issues involved
in drug delivery for topical agents in AA.
Existing means of delivery may be
appropriate for small molecules, but
larger polar molecules, such as anti-
bodies or peptides, will need enhanced
delivery systems, preferably through the
hair follicle. The practicality of systemic
drug delivery will depend on the bal-
ance of benefit and risk.
Standardization of All Future AA
Clinical Trails
Irv Katz, MD, University of Minnesota,
and Jerry Shapiro, MD, FRCPC, Univer-
sity of British Columbia, reviewed the
issues involved in clinical trial design
and execution in AA. It is clear that
previous studies in AA have been inade-
quate; a recent Cochrane review con-
cluded that there is no convincing
evidence of lasting effect of any treat-
ment in AA (Cochrane review). It is clear
that we need to have better standardized
trial design with unambiguous and reli-
able end points, physician and patient
evaluations of effect, and biomarkers to
quantitate effectiveness.
Conclusions from the Summit
1. Multiple highly promising drugs are
available for testing in AA, based on
findings of the recent GWAS study
and on drugs available from other
autoimmune disease programs.
2. There are abundant, excellent
choices for topical and systemic
therapy for AA, but we cannot afford
another clinical trial from which we
learn nothing.
3. The AA research community lacks a
uniform clinical research protocol
with validated biomarkers to study
clinical and mechanistic response to
treatment.
4. The Cochrane review on AA treat-
ments did not give proper considera-
tion to ‘‘half head’’ studies that show
effectiveness for topical diphency-
prone contact sensitization therapy.
Such studies will be useful in asses-
sing future topical treatments for AA.
5. Well-coordinated, multi-center trials
using a robust clinical trial protocol
with excellent biomarkers and un-
ambiguous end points are essen-
tial in establishing the safety and
efficacy of new drugs for use in
treating AA.
Action Agenda from the NAAF Clinical
Summit
1. Produce a Summary of the Summit
to distribute to drug companies and
NAAF donors
2. Mine the NAAR data and publish
QOL data on AA
3. Develop a uniform AA clinical
research platform that stratifies
extent and duration, has a crossover
component, and has an unambigu-
ous end point
4. Research the literature for all AA
biomarkers and submit a paper for
publication
5. Research and submit to the task
force the biomarkers from the
Raptiva study
6. Develop a plan for developing a
translational platform with bio-
markers (skin, serum, whole blood,
RNA, DNA)
7. Develop a plan for approaching
the 22 pharmaceutical companies
developing drugs that need to be
pursued for AA
8. Apply for the NIAMS Clinical Pilot
and Feasibility Studies. Multiple
investigators need to submit multi-
ple distinct proposals.
9. Schedule regular meetings of the
AA Clinical Task Force
10. Change the name of the registry in
October 2011 to Alopecia Areata
Clinical Trials Registry
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11. Empower NAAF to become a
research ‘‘concierge’’. NAAF will
seek partners, establish collabora-
tions, invite investors, negotiate
with drug companies to test new
drugs in AA models or humans, and
develop partnerships with industry
and/or the NIH for cost sharing in
research.
‘What’s Past is Prologue’
The maturation and re-organization of
AA research through the efforts of NAAF
and three highly successful research
summits has provided the foundation
on which the fourth summit was built.
The AA and hair research communities
are well integrated and are working
collaboratively, both to promote
research into the cause and mechanisms
of AA and to develop better treatment
for patients as quickly as possible. The
cooperative clinical research network
that has emerged from the collabora-
tions formed in the NAAR is a highly
promising development that will work
to provide patients with new treatments.
It is informative to compare the pro-
gress of four NAAF-Sponsored Research
Summits chronicled in this issue of the
Journal of Investigative Dermatology
Symposium Proceedings with the status
of research in AA in 2003 in the last
JID Symposium Proceedings devoted to
AA (Norris, 2003). The dividends of
this successful research reorganization
sponsored by NAAF and the great
success of the collaborative efforts of
the AA research community are evident
in the research articles published in this
issue.
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